ATRA
Atara Biotherapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$41.54M
P/E Ratio
1.88
EPS
$2.59
Beta
-0.29
52W High
$19.14
52W Low
$3.92
50-Day MA
$5.12
200-Day MA
$10.35
Dividend Yield
—
Profit Margin
27.10%
Forward P/E
232.56
PEG Ratio
0.00
About Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc., a commercially available T-cell immunotherapy company, develops treatments for cancer patients, autoimmune and viral diseases in the United States. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | $120.77M |
| Gross Profit (TTM) | $74.62M |
| EBITDA | $51.59M |
| Operating Margin | -339.60% |
| Return on Equity | -2015.00% |
| Return on Assets | 47.80% |
| Revenue/Share (TTM) | $9.63 |
| Book Value | $-5.26 |
| Price-to-Book | 16.14 |
| Price-to-Sales (TTM) | 0.34 |
| EV/Revenue | 0.357 |
| EV/EBITDA | 1.12 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -95.10% |
| Shares Outstanding | $8.51M |
| Float | $5.45M |
| % Insiders | 17.72% |
| % Institutions | 43.03% |
Historical Volatility
HV 10-Day
54.58%
HV 20-Day
59.76%
HV 30-Day
67.87%
HV 60-Day
101.33%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($9.33 target)
2
Buy2
Hold1
SellMore HEALTHCARE Stocks
Data last updated: 5/5/2026